Insulin resistance and parental obesity as predictors to response to therapeutic life style change in obese children and adolescents 10-18 years old.

J Adolesc Health

Pediatric Endocrinology and Diabetes Unit, Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Sackler School of Medicine, Tel-Aviv University, Israel.

Published: November 2008

Objective: To study insulin resistance and parental obesity as predictors of improvement in weight status in obese children and adolescents undergoing therapeutic life change intervention (TLC).

Design: A retrospective chart review.

Subjects: One hundred thirty-four adolescents 10 to 18 years old above the 95th percentile for body mass index (BMI), referred to the Center for Atherosclerosis Prevention from January through December 2003.

Measurements: BMI, fasting insulin, homeostasis model assessment insulin resistance (HOMA-IR). Weight management success was defined as BMI Z-score at final exam minus BMI Z-score at initial exam
Results: At baseline there were no differences between the groups in mean age, Tanner stage, gender, severity of obesity, lipid, and blood pressure levels. Insulin resistance was significantly higher in the NotS group compared to the S group as reflected by higher basal fasting insulin levels (21.8 +/- 12.3 vs. 15.8 +/- 9.0, p = .02), higher HOMA-IR (4.5 +/- 2.6 vs. 3.3 +/- 2.0, p = .02). After adjustment for age, gender, elevated blood pressure, abnormal lipid profile, baseline BMI Z-score, length of follow-up, and parental morbidity, an increase of 10 units of insulin resulted in a 3.13-fold (95% confidence interval [CI] 1.79-6.01) increased odds of failure. An increase in 1 unit of HOMA-IR resulted in 1.64-fold odds (95% CI 1.27-2.21) of failure. In the same multivariate logistic regression model the existence of obesity-associated morbidity in both parents was associated with 12.6-fold (95% CI 1.93-82.6) increased odds of failure.

Conclusions: Failing to respond to standard therapeutic lifestyle change intervention was dependent on baseline insulin resistance, and parental obesity-related comorbidity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jadohealth.2008.03.002DOI Listing

Publication Analysis

Top Keywords

insulin resistance
12
resistance parental
8
parental obesity
8
obesity predictors
8
therapeutic life
8
obese children
8
children adolescents
8
bmi z-score
8
insulin
4
predictors response
4

Similar Publications

Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation.

Biomed J

January 2025

Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address:

Background: Obesity and circadian rhythm disruption are significant global health concerns, contributing to an increased risk of metabolic disorders. Both adipose tissue and circadian rhythms play critical roles in maintaining energy homeostasis, and their dysfunction is closely linked to obesity. This study aimed to assess the effects of chronic low-dose SR9009, a REV-ERB ligand, on circadian disruption induced by constant light exposure in mice.

View Article and Find Full Text PDF

Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma.

Cancer Treat Rev

January 2025

Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Electronic address:

Immune-based combinations are the cornerstone of the first-line treatment of metastatic renal cell carcinoma patients, leading to outstanding outcomes. Nevertheless, primary resistance and disease progression is a critical clinical challenge. To properly address this issue, it is pivotal to understand the mechanisms of resistance to immunotherapy and tyrosine kinase inhibitors, that tumor eventually develop under treatment.

View Article and Find Full Text PDF

Ergosterol alleviates hepatic steatosis and insulin resistance via promoting fatty acid β-oxidation by activating mitochondrial ACSL1.

Cell Rep

January 2025

State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China. Electronic address:

Sterols target sterol-sensing domain (SSD) proteins to lower cholesterol and circulating and hepatic triglyceride levels, but the mechanism remains unclear. In this study, we identify acyl-coenzyme A (CoA) synthetase long-chain family member 1 (ACSL1) as a direct target of ergosterol (ES). The C-terminal domain of ACSL1 undergoes conformational changes from closed to open, and ES may target the drug-binding pocket in the acetyl-CoA synthetase-like domain 1 (ASLD1) of ACSL1 to stabilize the closed conformation and maintain its activity.

View Article and Find Full Text PDF

Resinacein S ameliorates the obesity in mice via activating the brown adipose tissue.

Pak J Pharm Sci

January 2025

Department of Endocrinology, Gongli Hospital of Shanghai Pudong New Area, School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.

Brown adipose tissue (BAT) is an ideal target organ for obesity treatment. Resinacein S is extracted from Ganoderma lucidum and can elevate Uncoupling protein 1 (UCP1) in cells, but its related effects at the animal level are not clear. The mice were fed with high-fat diet to construct obesity models and treated with Resinacein S.

View Article and Find Full Text PDF

The objective of this study was to evaluate the therapeutic effects of Chiglitazar combined with Rosa roxburghii Tratt (RRT) in inpatients diagnosed with psychiatric disorders and antipsychotic-induced metabolic syndrome (MetS).100 cases were included and divided into the Siglitazar group (n=50) and the Siglitazar + RRT group (n=50) Anthropometric measurements, lipid and glucose metabolism indicators, inflammatory markers and PANSS scores were assessed at baseline, 8 weeks and 12 weeks post-treatment. Both treatment groups exhibited significant reductions in waist circumference and improvements in lipid profiles and glucose metabolism indicators over the 12-week study period.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!